PRECLINICAL PUBLICATION · 2015

Optimization of multifunctional chitosan-siRNA nanoparticles for oral delivery applications, targeting TNF-alpha silencing in rats.

Rat / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

TNF-alpha siRNA in mannose-modified trimethyl chitosan-cysteine nanoparticles (en-MTC nanoparticles)

PMID 25662912 ↗2015Reported benefit

Optimization of multifunctional chitosan-siRNA nanoparticles for oral delivery applications, targeting TNF-alpha silencing in rats.

RatChemical/toxinSprague-DawleyMaleOral50 micrograms per kg siRNA

Model: Acute hepatic injury driven by systemic TNF-alpha

Orally delivered en-MTC nanoparticles at 50 micrograms per kg siRNA inhibited systemic TNF-alpha production, lowered TNF-alpha mRNA in liver, spleen and lung and protected rats from acute hepatic injury.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.